What is chimeric antigen receptor-T cell therapy?
By Alex Osiadacz
Roughly 620,000 new cases of lymphoma were diagnosed worldwide, according to the World Cancer Research Fund International's 2020 report. Survival rates have improved as advances develop in treatment, such as chimeric antigen receptor-T cell therapy (CAR-T cell therapy).
Learn more about CAR-T cell therapy from this "Mayo Clinic Minute" video:
CAR-T cell therapy is a personalized treatment giving hope to patients diagnosed with various lymphomas.
"Lymphoma in plain terms is essentially a cancer of your immune system," says Dr. Madiha Iqbal, a Mayo Clinic hematologist and oncologist.
Patients who are newly diagnosed with lymphoma are offered a combination of chemotherapy and antibody-based treatments. But for those who do not respond to two or more lines of such treatments, CAR-T cell therapy may be an option.
"Prior to the advent of CAR-T cell therapy, patients who had failed two lines of chemotherapy had a very poor survival of around six months," says Dr. Iqbal.
Receiving CAR-T cell therapy can take a few weeks as a patient's T cells, which normally help fight off infections, are collected and genetically engineered to target lymphoma.
After low-dose chemotherapy, the modified cells are infused back into the patient. These cells can then attack and destroy the lymphoma.
"Patients who had a very poor prognosis can now potentially be cured of their disease," says Dr. Iqbal.
For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, where social distancing and other safety protocols were followed.
A version of this story originally appeared on the Mayo Clinic News Network.